RxDoctor Payments Data

Leslie Crofford, MD

Rheumatology · Nashville, TNNPI 1710998760

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,810 of the $7,947 with a category attached, or 98.3%. UCB SA accounts for 98.3% of it on its own, with 2 other manufacturers making up the rest.

$7,947in general payments, 2019–2025

Across 6 payments — averaging $1324.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$8K
  • Genentech, Inc.$107
  • Amgen$30
$118,735in research payments, 2019–2025

Across 33 payments — averaging $3598.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Argenx US, Inc.$114K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$5K

What the payments were for

  • Consulting fees$7,81098%
  • Education$1372%

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA2$7,810
Genentech, Inc.2$107
Amgen2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,947 in reported general payments places this provider in the 55th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,803
Medicare patients
17
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept12$88,817
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$347

Paid to pharmacies, not to this prescriber.

Other rheumatology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →